WTX-330
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Trial Timeline
Dec 6, 2022 → Feb 5, 2025
NCT ID
NCT05678998About WTX-330
WTX-330 is a phase 1 stage product being developed by Werewolf Therapeutics for Advanced or Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT05678998. Target conditions include Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06939283 | Phase 1/2 | Active |
| NCT05678998 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors